Financial Performance - The company's operating revenue for Q1 2025 was RMB 323,134,237.51, representing a year-on-year increase of 0.81% compared to RMB 320,532,749.36 in the same period last year[7]. - The net profit attributable to shareholders of the listed company was a loss of RMB 11,910,593.71, compared to a loss of RMB 6,523,098.03 in the previous year, indicating a worsening performance[7]. - The basic and diluted earnings per share were both negative at RMB -0.02, worsening from RMB -0.01 in the previous year[7]. - Operating profit for Q1 2025 was a loss of RMB 8.31 million, compared to a profit of RMB 841,911.63 in Q1 2024[30]. - Net profit for Q1 2025 was a loss of RMB 10.54 million, compared to a loss of RMB 3.34 million in Q1 2024, indicating a worsening performance[30]. - The company reported a total comprehensive loss of RMB 10.65 million for Q1 2025, compared to a loss of RMB 2.96 million in Q1 2024[33]. Cash Flow - The net cash flow from operating activities was a negative RMB 58,387,506.08, compared to a negative RMB 53,158,582.98 in the same period last year[7]. - Cash inflow from operating activities for Q1 2025 was $278,458,588.43, an increase of 10.5% compared to $252,097,350.35 in Q1 2024[36]. - Cash outflow from operating activities for Q1 2025 was $336,846,094.51, up from $305,255,933.33 in Q1 2024, resulting in a net cash flow from operating activities of -$58,387,506.08[37]. - The net increase in cash and cash equivalents for Q1 2025 was -$59,948,143.08, compared to -$23,313,247.67 in Q1 2024[38]. - The ending balance of cash and cash equivalents for Q1 2025 was $350,624,246.30, down from $406,535,570.78 in Q1 2024[40]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 3,088,657,749.09, a slight increase of 0.07% from RMB 3,086,613,319.89 at the end of the previous year[9]. - The total liabilities as of March 31, 2025, were RMB 1.68 billion, an increase from RMB 1.67 billion as of December 31, 2024[27]. - Current liabilities totaled RMB 967,760,245.92, up from RMB 961,752,691.05, indicating an increase of approximately 0.8%[26]. - Total non-current assets were RMB 1,612,573,383.85, a slight decrease from RMB 1,616,549,071.25[25]. - The company's cash and cash equivalents decreased to RMB 433,792,851.69 from RMB 482,988,509.97, reflecting a decline of approximately 10.2%[24]. Shareholder Equity - The equity attributable to shareholders of the listed company decreased by 0.84% to RMB 1,075,096,336.77 from RMB 1,084,156,625.22 at the end of the previous year[9]. - Total equity attributable to shareholders was RMB 1.08 billion as of March 31, 2025, a slight decrease from RMB 1.08 billion as of December 31, 2024[27]. - The weighted average return on equity was -1.10%, down from -0.61% in the same period last year[7]. Research and Development - Research and development expenses increased significantly, contributing to the net loss for the period[14]. - Research and development expenses increased significantly to RMB 23.20 million in Q1 2025, up from RMB 14.17 million in Q1 2024, representing a growth of 63.73%[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,339[17]. - The company completed the initial grant registration of its 2023 restricted stock incentive plan on December 28, 2023[21]. - A total of 180,000 shares of restricted stock will be repurchased and canceled due to five individuals no longer meeting the incentive criteria[22]. - The company aims to enhance its long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders, the company, and employees[21].

年 報 2024 目錄 | 公司資料 | 2 | | --- | --- | | 主席報告 | 3 | | 董事會報告 | 5 | | 企業管治報告 | 33 | | 風險管理報告 | 44 | | 環境、社會及管治報告 | 52 | | 獨立核數師報告 | 86 | | 綜合損益表 | 92 | | 綜合全面收益表 | 93 | | 綜合財務狀況表 | 94 | | 綜合權益變動表 | 96 | | 綜合現金流動表 | 98 | | 財務報告書附註 | 99 | | 主要附屬公司資料 | 188 | | 主要聯營公司資料 | 196 | | 主要合營企業資料 | 197 | | 共同經營企業資料 | 198 | | 主要物業附表 | 199 | | 財務資料概要 | 203 | | 補充財務資料 | 204 | 頁次 公司資料 名譽主席* 李文正博士 董事會 執行董事 李棕博士 （主席） 李聯煒先生，BBS, JP （副主席） 李國輝先生 （行政總裁） 李江先生 非執行董事 李澤培先生，SBS, OBE, JP 陳念良先生 獨立非執行董事 徐景輝先生 容夏谷先生 吳敏燕女士 委員會 審核委員會 容夏谷先生 ...

目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 主席報告 | 4 | | 董事及高級管理層 | 6 | | 管理層討論及分析 | 9 | | 環境、社會及管治報告 | 18 | | 董事會報告 | 51 | | 企業管治報告 | 68 | | 獨立核數師報告 | 83 | | 綜合損益及其他全面收益表 | 89 | | 綜合財務狀況表 | 91 | | 綜合權益變動表 | 93 | | 綜合現金流量表 | 94 | | 綜合財務報表附註 | 96 | | 財務資料摘要 | 153 | | 主要房地產摘要 | 154 | 公司資料 董事會 執行董事 江陳鋒先生 （主席） 張秀華女士 韓林先生 非執行董事 林倩如女士 獨立非執行董事 崔士威先生 林俊才先生 鄒耀明先生 執行委員會 江陳鋒先生 （主席） 張秀華女士 韓林先生 審核委員會 鄒耀明先生 （主席） 崔士威先生 林俊才先生 薪酬委員會 崔士威先生 （主席） 林俊才先生 鄒耀明先生 提名委員會 江陳鋒先生 （主席） 林俊才先生 鄒耀明先生 註冊辦事處 P.O. Box 31119 Grand Pavilion Hibiscu ...

年報 2024 Annual Report w i t h H u n g F o o k T o n g p n d a t w i n s ' 1 0 0 d a y s r o d u c t s C e l e b r a t e p a b i r t h d a y 目錄 | 公司資料 | 2 | | --- | --- | | 二零二四年大事記 | 4 | | 主席的話 | 6 | | 管理層討論及分析 | 9 | | 環境、社會及管治 | 16 | | 獎項及嘉許 | 18 | | 董事及高級管理層 | 19 | | 董事會報告 | 23 | | 企業管治報告 | 34 | | 獨立核數師報告 | 49 | | 綜合全面收益表 | 57 | | 綜合財務狀況表 | 59 | | 綜合權益變動表 | 61 | | 綜合現金流量表 | 62 | | 綜合財務報表附註 | 63 | | 五年財務概要 | 136 | 公司資料 註冊成立地點 開曼群島 董事會 執行董事 謝寶達先生 （主席） 司徒永富博士 （行政總裁） 黃佩珠女士 獨立非執行董事 喬維明先生 （於二零二四年三月二十五日辭任） 冼日明教授 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （H股股份代碼：00317） 2025年第一季度報告 重要內容提示 中船海洋與防務裝備股份有限公司（「本公司」或「公司」）董事（「董事」）會（「董事會」）、監 事會及董事、監事、高級管理人員保證季度報告內容的真實、準確、完整，不存在虛假 記載、誤導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 公司負責人、主管會計工作負責人及會計機構負責人（會計主管人員）保證本季度報告中 財務信息的真實、準確、完整。 本報告期比 上年同期增減 | 項目 | 本報告期 | 上年同期 | 變動幅度(%) | | --- | --- | --- | --- | | 營業收入 | 3,641,442,907.15 | 2,806,869,058.01 | 29.73 | | 歸屬於上市公司股東的 | | | | | 淨利潤 | 184,464,01 ...

公司資料 2 主席報告 3 管理層討論及分析 4 董事及高級管理層履歷 11 企業管治報告 14 董事會報告 25 環境、社會及管治報告 34 獨立核數師報告 62 綜合損益及其他全面收益表 67 綜合財務狀況表 68 綜合權益變動表 70 綜合現金流量表 71 綜合財務報表附註 73 五年財務概要 132 目 錄 公司資料 董事會 執行董事 黃春興先生 （主席及行政總裁） 黃康福先生 范佳思女士 獨立非執行董事 楊德泉先生 何永深先生 趙家凱先生 審核委員會 楊德泉先 生（主席） 何永深先生 趙家凱先生 薪酬委員會 何永深先生 （主席） 楊德泉先生 趙家凱先生 黃康福先生 提名委員會 趙家凱先生 （主席） 楊德泉先生 何永深先生 黃康福先生 公司秘書 文潤華先生 （ACG, HKACG） 授權代表 黃康福先生 文潤華先生 新加坡總部及主要營業地點 7 Keppel Road, #03-20/21/22/23/24 Tanjong Pagar Complex Singapore 089053 香港主要營業地點 香港九龍 紅磡德豐街22 號 海濱廣場二座13樓1307A室 開曼群島主要股份過戶登記處 Ocori ...

Financial Performance - In 2024, the company achieved a revenue record of RMB 4,052.3 million, representing a year-on-year growth of 90.8%[9] - Gross profit reached RMB 1,239.8 million, a significant increase of 121.6%, with a gross margin of 30.6%[9] - Net profit surged by 277.2% to RMB 1,069.6 million, reflecting operational leverage and strict cost control measures[9] - Revenue for the year ended December 31, 2024, increased by 90.8% to RMB 4,052.3 million[22] - Gross profit for the year ended December 31, 2024, increased by 121.6% to RMB 1,239.8 million[22] - Net profit for the year ended December 31, 2024, increased by 277.2% to RMB 1,069.6 million[22] - Adjusted net profit for the year ended December 31, 2024, increased by 184.8% to RMB 1,174.0 million[22] - The company’s revenue increased by 90.8% from RMB 2,123.8 million for the year ended December 31, 2023, to RMB 4,052.3 million for the year ended December 31, 2024[73] - Adjusted net profit increased by 184.8% from RMB 412.3 million for the year ending December 31, 2023, to RMB 1,174.0 million for the year ending December 31, 2024[95] - Basic earnings per share grew by 217.9% from RMB 0.28 for the year ending December 31, 2023, to RMB 0.89 for the year ending December 31, 2024[96] Operational Expansion - The company expanded its global footprint and enhanced execution capabilities, with significant progress in its first overseas production base in Singapore[7] - The total number of ongoing integrated projects increased from 143 as of December 31, 2023, to 194 as of December 31, 2024[22] - The company is expanding its production capacity and attracting talent to meet the growing demand for bioconjugate drug CRDMO services globally[19] - The company is expanding its production capacity for antibody intermediates in Wuxi, China, and building new facilities in Singapore to meet growing demand for bioconjugate drugs[42] - The new Singapore facility is expected to start operations by the end of 2025, with four production lines planned for clinical and commercial production[45] - The company operates integrated CRDMO services from drug discovery to commercialization across its bases in Shanghai, Wuxi, and Changzhou[42] Research and Development - The proprietary WuXiDARx™ technology has successfully developed 45 preclinical candidates and 7 clinical projects, addressing diverse R&D needs[10] - The company launched innovative linker and payload technologies, including X-LinC, to optimize the therapeutic potential of ADCs[10] - The company is focused on optimizing ADC production processes to ensure consistency and successful scale-up for commercialization[39] - The company plans to submit 30 IND applications in 2024 and deliver over 300 batches of GMP-compliant products[1] - The company aims to enhance its platform to drive the development of the bioconjugate drug industry, benefiting global biopharmaceutical partners and patients[33] Client and Market Growth - The company ranked second globally and first in China in the ADC CRDMO sector based on 2022 revenue, with a strategy focused on empowering and winning molecular partnerships[59] - As of December 31, 2024, the company had 499 clients, a significant increase from 345 in 2023, reflecting a growing and diversified customer base[59] - Revenue from North America grew significantly, contributing RMB 2,030.4 million (50.1% of total revenue) in 2024, compared to RMB 851.9 million (40.1%) in 2023[74] - The company generated RMB 3,767.2 million from ADC projects, accounting for 93.0% of total revenue in 2024, up from 88.9% in 2023[79] Financial Management - Financial costs increased by 331.9% from RMB 0.7 million for the year ending December 31, 2023, to RMB 3.2 million for the year ending December 31, 2024, primarily due to increased interest expenses from bank loans[87] - Other income rose by 149.1% from RMB 92.3 million for the year ending December 31, 2023, to RMB 229.9 million for the year ending December 31, 2024, mainly driven by increased bank interest income[88] - The company maintains a centralized management of financial activities to control and reduce funding costs[111] - The company plans to manage foreign currency risk through forward contracts and hedge accounting for derivatives[120] Sustainability and ESG Commitments - The company implemented strict waste management and emission control standards, contributing to its ESG commitments[11] - The company aims to reduce greenhouse gas emissions by 50% by 2030, using 2021 as the baseline year, while expanding its operations[65] - The company is committed to social responsibility and sustainable growth, with details to be disclosed in its environmental, social, and governance report[199] Governance and Leadership - The board of directors includes experienced professionals with over 20 years in the biotechnology industry, such as Dr. Chen Zhisheng and Dr. Zhou Weichang[141][142] - The company has appointed Ulf Grawunder, an experienced entrepreneur in the life sciences sector, as an independent non-executive director[145] - The company emphasizes the importance of independent judgment in its governance structure, as highlighted by the roles of independent directors[145] - The independent non-executive directors have confirmed their independence as per the listing rules for the fiscal year ending December 31, 2024[165] Risks and Challenges - The company faces significant risks including potential declines in customer spending and demand, which could adversely impact its business, especially given the early-stage development of its products[200] - Increased competition in the industry may lead to customer attrition, affecting the company's market position[200] - The company's growth strategies and business expansion plans may not succeed, which could negatively impact its operations and financial performance[200] - The company may face challenges in successfully developing new technologies and improving existing ones to maintain its competitive edge[200]

Sunny Side Up Culture Holdings Limited 光尚文化控股有限公司 2024 年報 2024 年報 Sunny Side Up Culture Holdings Limited ANNUAL REPORT 光尚文化控股有限公司 Sunny Side Up Culture Holdings Limited 光尚文化控股有限公司 ANNUAL REPORT 2024 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶來較高投資 風險。有意投資的人士應了解投資該等公司的潛在風險，並應經過審慎周詳考慮後方可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風 險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不對因本報告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失 承擔任何責任。 本報告乃遵照香港聯合交 ...

2024 年 報 由於GEM 上市公司一般為中小型公司，在GEM 買賣的證券可能會較於主板買賣的證券承受較大的市場波動風 險，同時無法保證在GEM 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並 明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（吉輝控股有限公司（「本公司」）各董事（「董事」）願共同及個別對此承擔全部責任）乃遵照聯交所GEM 證券上市規則（「GEM 上市規則」）的規定而提供有關本公司的資料。各董事經作出一切合理查詢後確認，就彼 等所深知及確信，(1) 本報告所載資料在所有重要方面均屬準確及完整，不含誤導及欺騙成分；(2) 本報告並無 遺漏其他事宜，以致本報告內任何聲明或本報告產生誤導；(3) 於本報告內表達的所有意見均經審慎及周詳考 慮後始行作出，並依據公平合理的基準及假設。 本報告原文乃以英文編製，其後翻譯成中文。中英文版本如有任何歧義，概以英文版本為準。 目錄 KPM HOLDING LIMITED 吉輝控股有限公司 ANNUAL REPORT 2024 年報 ...

東莞農村商業銀行股份有限公司 Dongguan Rural Commercial Bank Co., Ltd. 股份代號：9889 （於中華人民共和國註冊成立的股份有限公司） 年度報告 2024 年 度 報 告 2024 目 錄 | 重要提示 | | 2 | | --- | --- | --- | | 釋義 | | 4 | | 董事長致辭 | | 8 | | 第一章 | 簡介和業務概要 | 11 | | 第二章 | 會計數據和財務指標摘要 | 16 | | 第三章 | 管理層討論與分析 | 20 | | | 一、總體經營情況分析 | 21 | | | 二、主要經營數據 | 21 | | | 三、業務發展整體情況 | 54 | | | 四、業務運作 | 55 | | | 五、風險管理情況 | 59 | | | 六、環境分析與未來展望 | 68 | | 第四章 | 環境、社會及管治 | 70 | | 第五章 | 三農金融服務情況 | 75 | | 第六章 | 股本變動及股東情況 | 80 | | 第七章 | 企業管治報告 | 88 | | 第八章 | 董事會報告 | 131 | | 第九章 | 監事會報告 | 1 ...